GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
Two years after pulling Blenrep from the market, GSK is positioning for a relaunch. This time, the company says it’s coming ...
GSK (GSK) announced that the National Medical Products Administration, NMPA, of China has accepted for review a new drug application, NDA, for ...
Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...
As part of the deal, GSK will pay Relation $45 million in upfront payments, which includes an equity investment of $15 million.
Hosted on MSN2d
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPDGSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback